In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical response to dupilumab can be differentiated on a molecular basis.

DC-15442 is a potent small molecule STAT6 inhibitor, which is not a degrader or prodrug, being advanced as a safe dupilumab-in-a-pill alternative for patients BOSTON, June 10, 2025 /PRNewswire ...